{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:50Z","timestamp":1787162450773,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy and adverse events of bevacizumab (BEV) combined with temozolomide (TMZ) in the treatment of glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCT) involving BEV combined with TMZ in the treatment of glioma were searched using PubMed, Embase and Cochrane library, and a comprehensive meta-analysis was conducted. The primary outcomes were overall survival time (OS) and progression-free survival time (PFS), and the secondary outcome was adverse events. Researchers conducted literature screening, data extraction and quality assessment according to inclusion and exclusion criteria. RevMan 5.3 software was used for meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 8 prospective RCTs of 3,039 cases were included in the meta-analysis. Meta-analysis showed that compared with TMZ alone, BEV combined with TMZ could significantly improve PFS, OS and complete remission rate (CR). A total of 6 studies reported related adverse events, mainly including thrombocytopenia, neutropenia, leukopenia, anemia and fatigue. Combination therapy may have more adverse events but no serious consequences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of BEV and TMZ had a better therapeutic effect on glioblastoma, significantly prolonged the survival time of patients and improved the quality of life. However, some patients are afflicted with the adverse events of combination therapy, and subsequent studies should continue to conduct larger, multi-center RCTs to confirm the findings and explore in depth how to minimize and manage adverse events effectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1419038","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:47:16Z","timestamp":1719881236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"11","author":[{"given":"SiYao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LanYin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e2254","DOI":"10.1002\/onco.13971","article-title":"A long-term extension study of bevacizumab in patients with solid tumors","volume":"26","author":"Oza","year":"2021","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1007\/s00415-023-11600-w","article-title":"Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?","volume":"270","author":"Smolenschi","year":"2023","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"828","DOI":"10.18999\/nagjms.85.4.828","article-title":"An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile","volume":"85","author":"Sato","year":"2023","journal-title":"Nagoya J Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11060-021-03834-3","article-title":"Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation","volume":"154","author":"Cardona","year":"2021","journal-title":"J Neuro Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"106661","DOI":"10.1016\/j.ejps.2023.106661","article-title":"Specific transport of temozolomide does not override DNA repair-mediated chemoresistance","volume":"195","author":"Bahrami","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1139\/bcb-2022-0321","article-title":"HSPA4 regulated glioma progression via activation of AKT signaling pathway","volume":"102","author":"Yuan","year":"2024","journal-title":"Biochem Cell Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/02688697.2021.1884648","article-title":"The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme","volume":"38","author":"Witte","year":"2024","journal-title":"Brit J Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4274\/dir.2024.232550","article-title":"Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis","author":"Liu","year":"2024","journal-title":"Diagn Interven Radiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1007\/s00330-022-09164-w","article-title":"Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort","volume":"33","author":"Kim","year":"2023","journal-title":"Eur Radiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11060-023-04248-z","article-title":"Dose-dependent efficacy of bevacizumab in recurrent glioblastoma","volume":"161","author":"Melhem","year":"2023","journal-title":"J Neuro Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e14041","article-title":"Efficacy and safety study of fotemustine and bevacizumab in patients with recurrent glioblastoma","volume":"40","author":"S\u00e1nchez Escudero","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"959072","DOI":"10.3389\/fonc.2022.959072","article-title":"Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas","volume":"12","author":"Weber","year":"2022","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e30874","DOI":"10.1002\/pbc.30874","article-title":"A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas","volume":"71","author":"Krystal","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial","volume":"19","author":"van den Bent","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref18","first-page":"145","article-title":"Efficacy of bevacizumab combined with temozolomide dose-dense regimen on recurrent glioma","volume":"26","author":"Li","year":"2021","journal-title":"J BUON"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11060-015-1791-4","article-title":"Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials","volume":"123","author":"Carlson","year":"2015","journal-title":"J Neuro Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11060-016-2065-5","article-title":"Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial","volume":"127","author":"Balana","year":"2016","journal-title":"J Neuro Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/neuonc\/nov300","article-title":"Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy","volume":"18","author":"Saran","year":"2016","journal-title":"Neuro Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JCO.2010.30.2729","article-title":"Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme","volume":"29","author":"Lai","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"New Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"TPS2070","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2070","article-title":"Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma","volume":"39","author":"Campian","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1191226","DOI":"10.3389\/fneur.2023.1191226","article-title":"Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma","volume":"14","author":"Kassubek","year":"2023","journal-title":"Front Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s43856-023-00347-0","article-title":"Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial","volume":"3","author":"Ahluwalia","year":"2023","journal-title":"Commun Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.3390\/cancers14225522","article-title":"Bevacizumab beyond progression for newly diagnosed glioblastoma (BIOMARK): phase II safety, efficacy and biomarker study","volume":"14","author":"Nagane","year":"2022","journal-title":"Cancers"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jjco\/hyac004","article-title":"Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma","volume":"52","author":"Furuse","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of bevacizumab in recurrent glioblastoma: a scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s11547-021-01381-5","article-title":"Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients","volume":"126","author":"Detti","year":"2021","journal-title":"Radiol Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11060-024-04593-7","article-title":"Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response","volume":"167","author":"Bobholz","year":"2024","journal-title":"J Neuro Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"948933","DOI":"10.3389\/fonc.2022.948933","article-title":"Case report: the effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1200\/JCO.22.02772","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"41","author":"Friedman","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11060-023-04544-8","article-title":"An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma","volume":"166","author":"Tanaka","year":"2024","journal-title":"J Neuro Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1186\/s13063-019-3741-5","article-title":"Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial","volume":"20","author":"Wang","year":"2019","journal-title":"Trials"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11060-022-04162-w","article-title":"Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis","volume":"160","author":"Wang","year":"2022","journal-title":"J Neuro Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12032-018-1198-0","article-title":"Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study","volume":"35","author":"Garcia","year":"2018","journal-title":"Med Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2176\/nmc.oa.2018-0111","article-title":"Boron neutron capture therapy combined with early successive bevacizumab treatments for recurrent malignant gliomas - a pilot study","volume":"58","author":"Shiba","year":"2018","journal-title":"Neurol Med Chir"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2018-99-116938","article-title":"Arterial and venous thromboembolic safety of bevacizumab in patients with high grade gliomas","volume":"132","author":"Lee","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1419038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:47:22Z","timestamp":1719881242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1419038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":42,"alternative-id":["10.3389\/fmed.2024.1419038"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1419038","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"article-number":"1419038"}}